Navigation Links
GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies
Date:6/28/2011

IRVINE, Calif., June 28, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of high quality antibodies, is pleased to announce that they will be launching a full line of zebrafish antibodies.

Zebrafish have been increasingly utilized as a model organism for scientific research. Due to their short lifecycles and relatively large clutch sizes, they are a useful model for genetic studies. Zebrafish eggs are externally fertilized; therefore, researchers can control and manipulate the embryos from the moment of fertilization. In addition, their embryos are transparent, so researchers are able to observe the changes that occur throughout the developmental stages of the embryo.

"We believe the zebrafish is an excellent model organism for biological research," said Dr. Kristina Beiswenger, Product Specialist at GeneTex, "however, this field has long been overlooked and lacks quality antibody reagents. GeneTex is fully committed to developing high quality antibodies specifically validated with zebrafish samples. We will continue to expand this product line to satisfy the needs of zebrafish research."

Many zebrafish tissues and organ systems, including the kidney, pancreas, bones and heart, are comparable to those of higher mammals and humans. The relatively large size, large number and external development of zebrafish embryos make them especially agreeable to manipulation by a variety of chemical, physical and genetic methods.

GeneTex is launching one of the largest collections of zebrafish antibodies that are validated for western blotting, immunofluorescence (ICC/IF), immunohistochemistry (IHC) and other applications. Almost all of the antibodies in the line are antigen-affinity purified, which results in higher quality antibodies.

For additional information on GeneTex's full line of zebrafish antibodies, call toll-free 877-GENETEX (436-3839) or visit www.GeneTex.com/zebrafish.

About GeneTex:

GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex has over 35,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.  


'/>"/>
SOURCE GeneTex
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
4. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
5. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
6. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
7. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
10. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
11. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):